Sugi Predict

Sugi Predict / Compounds / SCHEMBL479035

SCHEMBL479035

SCHEMBL479035

CC(C)(C)OC(=O)N[C@@H](Cc1cccnc1)C(=O)O

nearest known ligand 0.61

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ACE P12821 1/20 0.61
▸ CYP3A4 P08684 9/20 0.56
▸ SCN9A Q15858 1/20 0.54
▸ CTSS P25774 2/20 0.54
▸ CTSL P07711 1/20 0.54
▸ CTSB P07858 1/20 0.54
▸ CTSK P43235 1/20 0.54
▸ PPARA Q07869 2/20 0.53
▸ PPARG P37231 1/20 0.53
▸ GPR132 Q9UNW8 1/20 0.52
▸ ITGB3 P05106 1/20 0.52
▸ ITGA2B P08514 1/20 0.52
▸ ITGA4 P13612 1/20 0.50
▸ ITGB7 P26010 1/20 0.50
▸ PTPN1 P18031 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30547269 1.00 ACE (0.61) ACECYP3A4SCN9ACTSSCTSL
SCHEMBL30655780 1.00 ACE (0.61) ACECYP3A4SCN9ACTSSCTSL
SCHEMBL29401567 1.00 ACE (0.61) ACECYP3A4SCN9ACTSSCTSL
SCHEMBL606221 1.00 ACE (0.61) ACECYP3A4SCN9ACTSSCTSL
SCHEMBL479037 1.00 ACE (0.61) ACECYP3A4SCN9ACTSSCTSL
SCHEMBL3820572 0.91 ACE (0.53) ACECYP3A4SCN9ACTSSCTSL
SCHEMBL2367464 0.90 ACE (0.52) ACECYP3A4SCN9ACTSSCTSL
SCHEMBL13323784 0.90 ACE (0.52) ACECYP3A4SCN9ACTSSCTSL
SCHEMBL8125933 0.90 CYP3A4 (0.52) ACECYP3A4SCN9ACTSSCTSL
SCHEMBL29588090 0.90 CYP3A4 (0.52) ACECYP3A4SCN9ACTSSCTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 290 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116640091-A Synthetic method of Boc-3- (3-pyridyl) -L-alanine 上海吉奉生物科技有限公司 2023-08-25 — — CN claimed
US-20050239992-A1 Polyurethane composition which contains an uretdione group DEGUSSA AG (DE) 2005-10-27 — — US claimed
US-20260116857-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS PARDES BIOSCIENCES INC (US) 2026-04-30 — — US disclosed
EP-4702033-A1 DESMURAMYLPEPTIDE DIACIDS AS NOD2 AGONISTS AND USE THEREOF Imhotex Limited (GB) 2026-03-04 — — EP disclosed
US-20260015313-A1 AMINO ACID ACTIVE ESTER AND SALT THEREOF PEPTIDREAM INC (JP) 2026-01-15 — — US disclosed
US-20260008758-A1 LINEAR DIPEPTIDYL PEPTIDASE 1 INHIBITORS AND USES THEREOF INSMED INCORPORATED 2026-01-08 — — US disclosed
EP-4534524-A1 AMINO ACID ACTIVE ESTER AND SALT THEREOF PeptiDream Inc. (JP) 2025-04-09 — — EP disclosed
US-20250059157-A1 TLR7/8 ANTAGONISTS AND USES THEREOF MERCK PATENT GMBH (DE) 2025-02-20 — — US disclosed
US-12145911-B2 Inhibitors of cysteine proteases and methods of use thereof Pardes Biosciences, Inc. (US) 2024-11-19 — — US disclosed
WO-2024224093-A1 DESMURAMYLPEPTIDE DIEESTERS AS NOD2 AGONISTS AND USE THEREOF Imhotex Limited (GB) 2024-10-31 — — WO disclosed
WO-2024224086-A1 DESMURAMYLPEPTIDE DIACIDS AS NOD2 AGONISTS AND USE THEREOF Imhotex Limited (GB) 2024-10-31 — — WO disclosed
WO-1995035313-A1 3-AMINO-2-OXO-1-PIPERIDINEACETIC DERIVATIVES CONTAINING AN ARGININE MIMIC AS ENZYME INHIBITORS CORVAS INTERNATIONAL, INC. (US) 1995-12-28 — — WO disclosed
EP-0680488-A1 2,6-DIAMINOPURINE DERIVATIVES GLAXO GROUP LIMITED (GB) 1995-11-08 — — EP disclosed
US-5393875-A Hypotensive, cardiotonic and antiischemic agents HOFFMANN-LA ROCHE INC. (US) 1995-02-28 — — US disclosed
WO-1994017090-A1 2,6-DIAMINOPURINE DERIVATIVES GLAXO GROUP LIMITED (GB) 1994-08-04 — — WO disclosed
EP-0572909-A1 Amino acid derivatives as renin inhibitors F. HOFFMANN-LA ROCHE AG (CH) 1993-12-08 — — EP disclosed
EP-0509354-A2 Amino acid derivatives F. HOFFMANN-LA ROCHE AG (CH) 1992-10-21 — — EP disclosed
US-5091396-A Guanidinoalkanoylaspartylpyridine derivatives; anticoagulants MONSANTO CO. (US) 1992-02-25 — — US disclosed
EP-0454651-A2 Novel platelet-aggregation inhibitors MONSANTO COMPANY (US) 1991-10-30 — — EP disclosed
US-5037808-A Indolyl platelet-aggregation inhibitors MONSANTO CO. (US) 1991-08-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260116857-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS CTRC, CTRL, CTSL ACE 71/4885CYP3A4 1158/4885SCN9A 3133/4885
US-20260015313-A1 AMINO ACID ACTIVE ESTER AND SALT THEREOF NSUN3, BCAT1, SLC43A1 ACE 1944/4885CYP3A4 1322/4885SCN9A 914/4885
US-20250059157-A1 TLR7/8 ANTAGONISTS AND USES THEREOF TLR7, TLR8, TLR9 ACE 3963/4885CYP3A4 3093/4885SCN9A 2327/4885
US-20260008758-A1 LINEAR DIPEPTIDYL PEPTIDASE 1 INHIBITORS AND USES THEREOF DPP3, DPP7, DPP9 ACE 11/4885CYP3A4 655/4885SCN9A 411/4885
US-12145911-B2 Inhibitors of cysteine proteases and methods of use thereof CTRL, CTSV, CTSL ACE 77/4885CYP3A4 944/4885SCN9A 4427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.